



# *Divi's Laboratories Limited*

Date: July 19, 2024

To  
The Secretary  
**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra-Kurla Complex, Bandra (East)  
**MUMBAI – 400 051**

To  
The Secretary  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street  
**MUMBAI – 400 001**

Trading Symbol: **DIVISLAB**

Scrip Code: **532488**

Dear Sir/ Madam,

**Sub: US-FDA Inspection of Company's Unit-II manufacturing facility at Visakhapatnam, Andhra Pradesh**

**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We hereby inform that the US Food and Drug Administration (US-FDA) conducted a general cGMP inspection of the Company's Unit-II manufacturing facility at Chippada Village, Bheemunipatnam Mandal, Visakhapatnam, Andhra Pradesh from July 11, 2024 to July 19, 2024.

The US-FDA inspection is successfully completed with one procedural observation, which will be addressed in the stipulated period of time.

This is for your information and records.

Thanking you,

Yours faithfully,  
For **Divi's Laboratories Limited**

**M. Satish Choudhury**  
**Company Secretary & Compliance Officer**